Frederick Lief Ruberg, MD

Associate Professor, Medicine

Frederick Ruberg
75 E. Newton St Collamore Building

Biography

Dr. Ruberg’s clinical and research expertise is in the field of cardiac imaging including echocardiography and cardiovascular magnetic resonance imaging (CMR). Dr. Ruberg applies imaging in research designed to facilitate improved diagnosis and management of the infiltrative cardiomyopathy cardiac amyloidosis.

Other Positions

  • Associate Professor, Radiology, Boston University School of Medicine
  • Program Director, Pilot Translational & Clinical Studies Program, Clinical and Translational Science Institute, Boston University School of Medicine
  • Active Staff Privileges, Medicine, Boston Medical Center

Education

  • University of Pennsylvania School of Medicine, MD
  • Haverford College, BA

Publications

  • Published on 3/12/2018

    Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, Treibel TA, Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Native T1 and Extracellular Volume in Transthyretin Amyloidosis. JACC Cardiovasc Imaging. 2018 Mar 12. PMID: 29550324.

    Read at: PubMed
  • Published on 3/8/2018

    Jhaveri T, Sarosiek S, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V. Once AL amyloidosis: not always AL amyloidosis. Amyloid. 2018 Mar 08; 1-2. PMID: 29516761.

    Read at: PubMed
  • Published on 2/9/2018

    Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018 Mar; 25(1):62-67. PMID: 29424556.

    Read at: PubMed
  • Published on 2/1/2018

    Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, Connors LH. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ Heart Fail. 2018 Feb; 11(2):e004000. PMID: 29449366.

    Read at: PubMed
  • Published on 1/3/2018

    Maurer MS, Ruberg FL, Weinsaft JW. More Than Meets the Eye: Time for a New Imaging Paradigm to Test for Cardiac Amyloidosis. J Card Fail. 2018 Feb; 24(2):87-89. PMID: 29305971.

    Read at: PubMed
  • Published on 10/20/2017

    Arvanitis M, Chan GG, Jacobson DR, Berk JL, Connors LH, Ruberg FL. Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. Amyloid. 2017 Dec; 24(4):253-255. PMID: 29052438.

    Read at: PubMed
  • Published on 9/1/2017

    Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017 Sep 01; 18(9):1057-1064. PMID: 27965280.

    Read at: PubMed
  • Published on 7/24/2017

    Arun M, Brauneis D, Doros G, Shelton AC, Sloan JM, Quillen K, Ruberg FL, Sanchorawala V, Varga C. The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. Bone Marrow Transplant. 2017 09; 52(9):1349-1351. PMID: 28737773.

    Read at: PubMed
  • Published on 7/13/2017

    Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018 Jan; 28(1):10-21. PMID: 28739313.

    Read at: PubMed
  • Published on 6/21/2017

    Siddiqi OK, Ruberg FL. Challenging the myths of cardiac amyloidosis. Eur Heart J. 2017 Jun 21; 38(24):1909-1912. PMID: 28444296.

    Read at: PubMed

View 58 more publications: View full profile at BUMC

View all profiles